Get the Stockscreener App
3.18
0.00%
0.00
After Hours:
3.18
Anixa Biosciences Inc stock is traded at $3.18, with a volume of 175.32K.
It is up +0.00% in the last 24 hours and down -33.61% over the past month.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$3.18
Open:
$3.15
24h Volume:
175.32K
Relative Volume:
0.61
Market Cap:
$104.68M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-8.1538
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
+1.92%
1M Performance:
-33.61%
6M Performance:
-1.55%
1Y Performance:
+34.18%
1-Day Range:
$3.105
$3.25
1-Week Range:
$3.06
$3.25
52-Week Range:
$2.07
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.18 | 104.68M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Anixa Biosciences (ANIX) Expected to Announce Quarterly Earnings on Friday - MarketBeat
Anixa announces transfer of IND for breast cancer vaccine from Cleveland Clinic - MSN
Anixa Biosciences Inc (NASDAQ:ANIX) Sees Significant Increase in Short Interest - MarketBeat
Anixa Biosciences director Titterton buys $8,820 in common stock - MSN
Anixa Biosciences (STU:CY71) EV-to-OCF : -12.38 (As of Dec. 28, 2025) - GuruFocus
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Anixa Biosciences (FRA:CY71) EV-to-OCF : -12.43 (As of Dec. 22, 2025) - GuruFocus
Why analysts upgrade Anixa Biosciences Inc. stock2025 Risk Factors & Precise Buy Zone Identification - Улправда
Can Anixa Biosciences Inc. stock attract ESG capital inflowsMarket Sentiment Review & Low Drawdown Trading Techniques - Улправда
Is Anixa Biosciences Inc. stock gaining market shareEarnings Recap Report & AI Enhanced Trading Signals - Улправда
Why retail investors pile into Anixa Biosciences Inc. stock2025 Market Overview & Safe Capital Preservation Plans - Улправда
Is Anixa Biosciences Inc. (CY71) stock a buy for dividend portfolios2025 Macro Impact & Fast Exit Strategy with Risk Control - DonanımHaber
ANIX: Phase 1 Breast Cancer Vaccine Success Paves Way for Program Advancement - Smartkarma
Will Anixa Biosciences Inc. stock deliver better than expected guidanceJuly 2025 Selloffs & Capital Protection Trade Alerts - DonanımHaber
Gap Down: Is Anixa Biosciences Inc CY71 stock cheap by valuation metricsNew Guidance & Target Return Focused Stock Picks - moha.gov.vn
What is the fair value of Anixa Biosciences Inc. stock now2025 EndofYear Setup & Fast Gain Swing Alerts - Улправда
How strong is Anixa Biosciences Inc. stock balance sheetWeekly Profit Summary & Growth Focused Stock Pick Reports - Улправда
Aug Action: Why Anixa Biosciences Inc stock could be next big winnerMarket Movers & Fast Momentum Entry Tips - moha.gov.vn
Anixa Biosciences Inc (ANIX) director reports 16,000 share option exercise - Stock Titan
Anixa Biosciences takes over breast cancer vaccine IND from Cleveland Clinic - Investing.com Australia
Anixa Biosciences, Inc. (ANIX) Stock Price, News, Quote & History - Yahoo Finance
ANIX: Breast cancer vaccine phase I showed 75% robust immune response and strong safety profile - TradingView — Track All Markets
Anixa Biosciences falls on phase 1 data for breast cancer vaccine - MSN
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 - WV News
Cleveland Clinic transfers breast cancer vaccine IND to Anixa - marketscreener.com
Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine Developm - GuruFocus
Anixa Biosciences Announces Transfer of IND for Breast Cancer Va - GuruFocus
Anixa Biosciences takes over breast cancer vaccine IND from Cleveland Clinic By Investing.com - Investing.com South Africa
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic - Nasdaq
D. Boral Capital Maintains Anixa Biosciences (ANIX) Buy Recommendation - Nasdaq
Anixa Biosciences (ANIX) Shares Drop 21% After Phase 1 Vaccine D - GuruFocus
Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at D. Boral Capital - MarketBeat
ANIX: D. Boral Capital Maintains Buy Rating with $10 Price Targe - GuruFocus
Anixa Biosciences Reports Positive Phase 1 Trial Results - TipRanks
Anixa Biosciences Inc Announces Positive Phase 1 Data for Breast Cancer Vaccine - TradingView — Track All Markets
Anixa Biosciences Says Breast Cancer Vaccine Candidate Meets Key Endpoints in Phase 1 Trial - marketscreener.com
Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why - Benzinga
Anixa Biosciences Announces Positive Phase 1 Data for Investigat - GuruFocus
Anixa Biosciences (ANIX) Presents Promising Phase 1 Breast Cance - GuruFocus
Anixa Biosciences (NASDAQ: ANIX) presents final Phase 1 breast cancer vaccine data - Stock Titan
Anixa’s breast cancer vaccine shows positive Phase 1 results - Investing.com
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants - WV News
Cleveland Clinic Presents Final Results of Phase 1 Clinical Trial of Preventive Breast Cancer Vaccine Study - Cleveland Clinic Newsroom
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Anixa Biosciences (NASDAQ: ANIX) sets Dec. 15 talk on Phase 1 breast cancer vaccine - Stock Titan
Anixa Biosciences (NASDAQ: ANIX) unveils final Phase 1 breast cancer vaccine results at 2025 SABCS - Stock Titan
Will Anixa Biosciences Inc. (CY71) stock beat Nasdaq index returns2025 Risk Factors & Real-Time Stock Entry Alerts - Newser
Why Anixa Biosciences Inc. (CY71) stock is trending on social mediaPortfolio Update Report & Fast Momentum Stock Entry Tips - Newser
Will Anixa Biosciences Inc. stock see PE expansionWeekly Trading Summary & Risk Controlled Stock Pick Alerts - Newser
Is Anixa Biosciences Inc. stock undervalued vs historical averagesJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):